{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:28:54Z","timestamp":1788449334071,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA149848"],"award-info":[{"award-number":["R21CA149848"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA166280"],"award-info":[{"award-number":["R01CA166280"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA044579"],"award-info":[{"award-number":["P30CA044579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA166280"],"award-info":[{"award-number":["R01CA166280"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7020-19"],"award-info":[{"award-number":["7020-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["7020-19"],"award-info":[{"award-number":["7020-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"name":"J. P. Wilmot Cancer Center Pilot Award, University of Rochester Technologies Development Fund, University of Rochester CTSI, Empire Discovery Institute"},{"name":"Indiana University Simon Comprehensive Cancer Center (IUSCCC) Early Career Investigator Award and the Wells Center Translational\/Emerging Therapies Award."},{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM134864"],"award-info":[{"award-number":["R35GM134864"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008460","name":"U.S. Department of Health & Human Services | NIH | National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["R01AT012053"],"award-info":[{"award-number":["R01AT012053"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41375-025-02816-y","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:49:54Z","timestamp":1766126994000},"page":"293-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting IL-1\/IRAK1\/4 signaling in acute myeloid leukemia stem cells following treatment and relapse"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2913-9319","authenticated-orcid":false,"given":"Tzu-Chieh","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"LaMere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"LaMere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1647-8634","authenticated-orcid":false,"given":"Yu-Chiao","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2206-5720","authenticated-orcid":false,"given":"Baskar","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8225-4025","authenticated-orcid":false,"given":"Nikolay V.","family":"Dokholyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-239X","authenticated-orcid":false,"given":"Laura M.","family":"Calvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-8469","authenticated-orcid":false,"given":"Jane L.","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0869-3465","authenticated-orcid":false,"given":"Craig T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1124-9202","authenticated-orcid":false,"given":"Rakesh K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4349-1579","authenticated-orcid":false,"given":"Reuben","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-8815","authenticated-orcid":false,"given":"Michael W.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"2816_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3324\/haematol.2022.280802","volume":"108","author":"S Jaramillo","year":"2023","unstructured":"Jaramillo S, Schlenk RF. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica. 2023;108:342\u201352.","journal-title":"Haematologica"},{"key":"2816_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"2816_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.","journal-title":"Blood Cancer J"},{"key":"2816_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.2019004397","volume":"137","author":"J Stauber","year":"2021","unstructured":"Stauber J, Greally JM, Steidl U. Preleukemic and leukemic evolution at the stem cell level. Blood. 2021;137:1013\u20138.","journal-title":"Blood"},{"key":"2816_CR5","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","volume":"128","author":"TC Ho","year":"2016","unstructured":"Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O\u2019Dwyer KM, et al. Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016;128:1671\u20138.","journal-title":"Blood"},{"key":"2816_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17:1086\u201393.","journal-title":"Nat Med"},{"key":"2816_CR7","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1073\/pnas.0900089106","volume":"106","author":"R Majeti","year":"2009","unstructured":"Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci USA. 2009;106:3396\u2013401.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2816_CR8","doi-asserted-by":"publisher","first-page":"17ra19","DOI":"10.1126\/scitranslmed.3000349","volume":"2","author":"Y Saito","year":"2010","unstructured":"Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra19.","journal-title":"Sci Transl Med"},{"key":"2816_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547:104\u20138.","journal-title":"Nature"},{"key":"2816_CR10","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2816_CR11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H Dohner","year":"2021","unstructured":"Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2816_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00376-1","volume":"10","author":"N Daver","year":"2020","unstructured":"Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10:107.","journal-title":"Blood Cancer J"},{"key":"2816_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of Relapsed Acute Myeloid Leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"2816_CR14","doi-asserted-by":"crossref","unstructured":"Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218:e20201544.","DOI":"10.1084\/jem.20201544"},{"key":"2816_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-023-00422-1","volume":"12","author":"CTR Vegivinti","year":"2023","unstructured":"Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, et al. Role of innate immunological\/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Exp Hematol Oncol. 2023;12:60.","journal-title":"Exp Hematol Oncol"},{"key":"2816_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nri2691","volume":"10","author":"JE Sims","year":"2010","unstructured":"Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89\u2013102.","journal-title":"Nat Rev Immunol"},{"key":"2816_CR17","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC. Toll-like receptors and the control of immunity. Cell. 2020;180:1044\u201366.","journal-title":"Cell"},{"key":"2816_CR18","first-page":"cm1","volume":"3","author":"A Weber","year":"2010","unstructured":"Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3:cm1.","journal-title":"Sci Signal"},{"key":"2816_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ncb3346","volume":"18","author":"EM Pietras","year":"2016","unstructured":"Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18:607\u201318.","journal-title":"Nat Cell Biol"},{"key":"2816_CR20","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","volume":"21","author":"MA Smith","year":"2019","unstructured":"Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019;21:640\u201350.","journal-title":"Nat Cell Biol"},{"key":"2816_CR21","doi-asserted-by":"crossref","unstructured":"Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, et al. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife 2022;11:e78136.","DOI":"10.7554\/eLife.78136"},{"key":"2816_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2018-10-844654","volume":"133","author":"DA Sallman","year":"2019","unstructured":"Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133:1039\u201348.","journal-title":"Blood"},{"key":"2816_CR23","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","volume":"120","author":"L Barreyro","year":"2012","unstructured":"Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290\u20138.","journal-title":"Blood"},{"key":"2816_CR24","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"Carey","year":"2017","unstructured":"Carey, Edwards A, DKt, Eide CA, Newell L, Traer E, et al. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep. 2017;18:3204\u201318.","journal-title":"Cell Rep"},{"key":"2816_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35700-9","volume":"14","author":"A Villatoro","year":"2023","unstructured":"Villatoro A, Cuminetti V, Bernal A, Torroja C, Cossio I, Benguria A, et al. Endogenous IL-1 receptor antagonist restricts healthy and malignant myeloproliferation. Nat Commun. 2023;14:12.","journal-title":"Nat Commun"},{"key":"2816_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41584-022-00797-1","volume":"18","author":"L Broderick","year":"2022","unstructured":"Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat Rev Rheumatol. 2022;18:448\u201363.","journal-title":"Nat Rev Rheumatol"},{"key":"2816_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8\u201327.","journal-title":"Immunol Rev"},{"key":"2816_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","volume":"29","author":"J Bennett","year":"2022","unstructured":"Bennett J, Starczynowski DT. IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Curr Opin Hematol. 2022;29:8\u201319.","journal-title":"Curr Opin Hematol"},{"key":"2816_CR29","doi-asserted-by":"crossref","unstructured":"Miller JP, Kim KK, Khazan N, Snyder CW, Singh NA, Lamere E, et al. IL-1\u03b2\/IRAK4 axis promotes ovarian tumor development at the mesothelium injury sites. bioRxiv 2025.2003.2018.643950.2025.","DOI":"10.1101\/2025.03.18.643950"},{"key":"2816_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2816_CR31","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540:433\u20137.","journal-title":"Nature"},{"key":"2816_CR32","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1084\/jem.20180147","volume":"215","author":"K Mitchell","year":"2018","unstructured":"Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debre I, Narayanagari SR, et al. IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med. 2018;215:1709\u201327.","journal-title":"J Exp Med"},{"key":"2816_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nrd3800","volume":"11","author":"CA Dinarello","year":"2012","unstructured":"Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"2816_CR34","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","volume":"121","author":"M Askmyr","year":"2013","unstructured":"Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709\u201313.","journal-title":"Blood"},{"key":"2816_CR35","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA. 2010;107:16280\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2816_CR36","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood-2015-11-679985","volume":"128","author":"H Agerstam","year":"2016","unstructured":"Agerstam H, Hansen N, von Palffy S, Sanden C, Reckzeh K, Karlsson C, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128:2683\u201393.","journal-title":"Blood"},{"key":"2816_CR37","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/bjc.2014.513","volume":"112","author":"GW Rhyasen","year":"2015","unstructured":"Rhyasen GW, Starczynowski DT. IRAK signalling in cancer. Br J Cancer. 2015;112:232\u20137.","journal-title":"Br J Cancer"},{"key":"2816_CR38","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"2816_CR39","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1021\/acs.jcim.8b00905","volume":"59","author":"J Wang","year":"2019","unstructured":"Wang J, Dokholyan NV. MedusaDock 2.0: Efficient and Accurate Protein-Ligand Docking With Constraints. J Chem Inf Model. 2019;59:2509\u201315.","journal-title":"J Chem Inf Model"},{"key":"2816_CR40","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1021\/ci100218t","volume":"50","author":"F Ding","year":"2010","unstructured":"Ding F, Yin S, Dokholyan NV. Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model. 2010;50:1623\u201332.","journal-title":"J Chem Inf Model"},{"key":"2816_CR41","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","volume":"129","author":"DA Pollyea","year":"2017","unstructured":"Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells. Blood. 2017;129:1627\u201335.","journal-title":"Blood"},{"key":"2816_CR42","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","volume":"129","author":"A Shastri","year":"2017","unstructured":"Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. 2017;129:1586\u201394.","journal-title":"Blood"},{"key":"2816_CR43","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25:1315\u201321.","journal-title":"Nat Biotechnol"},{"key":"2816_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.blre.2019.04.004","volume":"36","author":"T Banerjee","year":"2019","unstructured":"Banerjee T, Calvi LM, Becker MW, Liesveld JL. Flaming and fanning: the spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019;36:57\u201369.","journal-title":"Blood Rev"},{"key":"2816_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996.","journal-title":"Front Immunol"},{"key":"2816_CR46","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1182\/blood-2017-06-780882","volume":"130","author":"EM Pietras","year":"2017","unstructured":"Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130:1693\u20138.","journal-title":"Blood"},{"key":"2816_CR47","doi-asserted-by":"crossref","unstructured":"Frisch BJ, Hoffman CM, Latchney SE, LaMere MW, Myers J, Ashton J, et al. Aged marrow macrophages expand platelet-biased hematopoietic stem cells via Interleukin1B. JCI Insight. 2019;5:e124213.","DOI":"10.1172\/jci.insight.124213"},{"key":"2816_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41556-022-01053-0","volume":"25","author":"CA Mitchell","year":"2023","unstructured":"Mitchell CA, Verovskaya EV, Calero-Nieto FJ, Olson OC, Swann JW, Wang X, et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. Nat Cell Biol. 2023;25:30\u201341.","journal-title":"Nat Cell Biol"},{"key":"2816_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/bloodadvances.2021004962","volume":"6","author":"S Stratmann","year":"2022","unstructured":"Stratmann S, Yones SA, Garbulowski M, Sun J, Skaftason A, Mayrhofer M, et al. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. Blood Adv. 2022;6:152\u201364.","journal-title":"Blood Adv"},{"key":"2816_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61647-8","volume":"16","author":"H Jiang","year":"2025","unstructured":"Jiang H, Fu D, Pasupuleti SK, Ramdas B, Long A, Ramadan AM, et al. ST2\/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche. Nat Commun. 2025;16:6580.","journal-title":"Nat Commun"},{"key":"2816_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61567-7","volume":"16","author":"D Fu","year":"2025","unstructured":"Fu D, Jiang H, Long A, Harris E, Guo H, Capitano ML, et al. Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33\/IL1RL1 pathway. Nat Commun. 2025;16:6369.","journal-title":"Nat Commun"},{"key":"2816_CR52","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003\u201318.","journal-title":"Immunity"},{"key":"2816_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ccr.2013.05.006","volume":"24","author":"GW Rhyasen","year":"2013","unstructured":"Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 2013;24:90\u2013104.","journal-title":"Cancer Cell"},{"key":"2816_CR54","doi-asserted-by":"crossref","unstructured":"Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Sci Transl Med. 20198;11.","DOI":"10.1126\/scitranslmed.aaw8828"},{"key":"2816_CR55","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3324\/haematol.2022.282349","volume":"108","author":"T Muto","year":"2023","unstructured":"Muto T, Walker CS, Agarwal P, Vick E, Sampson A, Choi K, et al. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023;108:2715\u201329.","journal-title":"Haematologica"},{"key":"2816_CR56","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood.2022018718","volume":"142","author":"J Bennett","year":"2023","unstructured":"Bennett J, Ishikawa C, Agarwal P, Yeung J, Sampson A, Uible E, et al. Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML. Blood. 2023;142:989\u20131007.","journal-title":"Blood"},{"key":"2816_CR57","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1038\/s41375-018-0112-2","volume":"32","author":"MM Hosseini","year":"2018","unstructured":"Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018;32:2374\u201387.","journal-title":"Leukemia"},{"key":"2816_CR58","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G, Winer ES, DeAngelo DJ, Tarantolo S, Sallman DA, Dugan J, et al. S129: Takeaim leukemia- a phase 1\/2A study of the IRAK4 inhibitor emavusertib (CA-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed\/refractory AML OR MDS. HemaSphere. 2022;6:30\u201331.","DOI":"10.1097\/01.HS9.0000843408.31385.3f"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02816-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02816-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02816-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:03:18Z","timestamp":1770278598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02816-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2816"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02816-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MWB, RKS, and LMC hold the patent for UR241-2 (CA3186896A1,\u00a0ZL202180054152.8). The remaining authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. All samples from AML patients or healthy donors were obtained with informed consent and in accordance with protocols approved by the Institutional Review Board (IRB) at the URMC (URCC: LEU 07047) and Roswell Park Comprehensive Cancer Center. Additionally, animal experiments conducted in this study were approved by the Institutional Animal Care and Use Committees (IACUCs) at the URMC (UCAR-2005-256E) and IUSM (#24038).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}